drugset / Trial / NCT07802184
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of GnP combined with SHR-1701 and Apatinib as first-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Timeline
- Start
- 2026-09-10
- Primary completion
- 2029-01-01
- Completion
- 2029-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 30 mg/kg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |